# Summary
BC007, a monoclonal antibody developed by Berlin Cures, shows promise in treating long COVID by targeting autoantibodies that attack heart and immune cells. The peptide received approval in over 30 countries, including those in Europe and Asia, based on clinical trial data suggesting it reduces symptom severity and improves quality of life in long COVID patients.
The FDA, however, has raised a significant concern halting U.S. approval. The agency requires additional safety data and long-term follow-up studies before clearing BC007 for American patients. The regulatory hesitation centers on questions about the antibody's sustained safety profile and potential long-term effects, particularly given that long COVID patients would likely need extended treatment periods.
BC007 works by neutralizing harmful autoantibodies involved in long COVID pathology. In clinical trials, patients receiving the treatment reported improvements in fatigue, exercise tolerance, and cognitive function. Some researchers believe the peptide addresses a root cause of long COVID rather than simply masking symptoms.
Despite FDA caution, patient advocates and researchers argue that approval delays prevent Americans from accessing a treatment already deemed safe enough for use abroad. Long COVID affects millions of people, many unable to work or maintain normal daily functioning, creating pressure for faster pathways to treatment access.
Berlin Cures continues working with the FDA to address regulatory concerns. The company has submitted additional data from extended follow-up studies and safety monitoring. Approval timelines remain uncertain, but experts expect the FDA decision within the next several years pending satisfactory evidence.
For long COVID patients in the U.S., the delayed approval represents another obstacle in an already frustrating journey toward treatment options for a condition that mainstream medicine is still working to fully understand.